Evidence mapPaperPMID 41511099Full record

ReviewPhysiological research2025

The Potential of MicroRNAs in the Context of Sarcopenic Obesity.

N Chobolová, Z Švagera, D Stejskal, M Bužga

Abstract readReview
In one paragraph

Review in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

N ChobolováDepartment of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic. marek.buzga@osu.cz.
Z Švagera
D Stejskal
M Bužga

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenic obesity (SO) is a complex pathological condition characterized by the simultaneous presence of excessive adipose tissue and the loss of muscle mass and strength. This combination leads to an increased risk of metabolic, cardiovascular, and functional complications. In recent years, there has been growing interest in the use of microRNAs (miRNA) as biomarkers capable of detecting early changes in body composition and predicting the progression of SO. MiRNAs are small noncoding RNA molecules that play a key role in regulating gene expression and cellular pathways related to inflammation, metabolism, and muscle trophism. This article summarizes current knowledge about miRNAs expression in patients with sarcopenic obesity, their regulatory functions, and their potential use in diagnostics and therapy. Key words microRNA " Sarcopenic obesity " miRNA " Biomarkers " Muscle atrophy " Inflammation.

Indexed as

MicroRNAsObesitySarcopeniaAnimalsBiomarkersHumansMuscle, SkeletalBiomarkersMicroRNAs

Identifiers

PMID41511099
PMCPMC12849797

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.